Dividend Reinvestment Plan underwritten

8 December 2022

DRP underwritten

On 18 November 2022 Ryman announced its interim dividend of 8.8 cents per share
payable on 16 December 2022.

Ryman also announced a dividend reinvestment plan (DRP), available for those eligible
shareholders that elect to participate by 5.00pm on 12 December 2022.

Under the DRP shares are offered at a 2.5% discount to the volume weighted average
sale price of Ryman shares traded through the NZX Main Board in the 5 trading days
starting on 8 December 2022.

Ryman advises that it has entered into an underwriting agreement with Craigs
Investment Partners Limited (CIP), under which CIP has agreed to underwrite shares
not taken up by Ryman shareholders in connection with the DRP on the same
essential terms as under the DRP. CIP’s appointment as underwriter is subject to
termination rights customary for an agreement of this nature.




Deborah Marris
Company Secretary

---

8 December 2022

Cleansing Notice – Underwritten Dividend Reinvestment Plan offer

Ryman Healthcare Limited (RYM) has entered into an underwriting agreement with
Craigs Investment Partners Limited (underwriter) under which the underwriter has
agreed to subscribe, or procure subscriptions, for shares not taken up under RYM’s
dividend reinvestment plan relating to the NZ 8.8 cents per share interim dividend to
be paid on 16 December 2022 at the same price as to be issued under the dividend
reinvestment plan (underwritten shares).

The shares to be issued are offered, and may be on-sold or transferred, in reliance
upon the exclusion in clause 19 of Schedule 1 to the Financial Markets Conduct Act
2013.

This notice is provided under clause 20(1)(a) of Schedule 8 of the Financial Markets
Conduct Regulations 2014 (Regulations).

As at the date of this notice, RYM is in compliance with its continuous disclosure
obligations that apply to it in relation to its quoted ordinary shares, and there is no
“excluded information” (as defined in clause 20(5) of Schedule 8 to the Regulations).

As at the date of this notice, RYM is in compliance with its financial reporting
obligations (as defined in clause 20(5) of Schedule 8 to the Regulations).

The issue of shares under the underwriting agreement and the subsequent on-sale or
transfer of such shares is not expected to have any effect on the control of RYM.


Deborah Marris
Company Secretary